Kath D. Watson

Manchester, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Nonmelanoma Skin Cancer Risk With JAK Inhibitors Compared to Interleukin-6 Receptor Inhibitors in Rheumatoid Arthritis: Results From a National Cohort Study.

Nonmelanoma Skin Cancer Risk With JAK Inhibitors Compared to Interleukin-6 Receptor Inhibitors in Rheumatoid Arthritis: Results From a National Cohort Study.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: March 03, 2026

Non-melanoma skin cancer risk with Janus kinase inhibitors compared to interleukin-6 receptor inhibitors in rheumatoid arthritis: results from a national cohort study.

Non-melanoma skin cancer risk with Janus kinase inhibitors compared to interleukin-6 receptor inhibitors in rheumatoid arthritis: results from a national cohort study.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: March 03, 2026

Association between body weight and tocilizumab effectiveness in rheumatoid arthritis: results from the BSRBR-RA.

Association between body weight and tocilizumab effectiveness in rheumatoid arthritis: results from the BSRBR-RA.

Journal: Rheumatology (Oxford, England)

Published: May 10, 2024

Potential impact of European Medicines Agency measures to minimize risk of serious side effects on JAKi prescribing and utilization in the UK.

Potential impact of European Medicines Agency measures to minimize risk of serious side effects on JAKi prescribing and utilization in the UK.

Journal: Rheumatology (Oxford, England)

Published: March 01, 2024

Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying anti-rheumatic drugs: does line of therapy matter?

Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying anti-rheumatic drugs: does line of therapy matter?

Journal: Rheumatology (Oxford, England)

Published: June 09, 2023

Outcomes following switching from etanercept originator to etanercept biosimilar in 1024 patients with RA: a matched-analysis of the BSRBR-RA.

Outcomes following switching from etanercept originator to etanercept biosimilar in 1024 patients with RA: a matched-analysis of the BSRBR-RA.

Journal: Rheumatology (Oxford, England)

Published: April 21, 2023

Socioeconomic deprivation is associated with reduced response and lower treatment persistence with TNF inhibitors in rheumatoid arthritis.

Socioeconomic deprivation is associated with reduced response and lower treatment persistence with TNF inhibitors in rheumatoid arthritis.

Journal: Rheumatology (Oxford, England)

Published: March 09, 2023

Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA.

Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA.

Journal: Rheumatology (Oxford, England)

Published: January 06, 2023

Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis.

Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis.

Journal: Rheumatology (Oxford, England)

Published: January 05, 2022

Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register.

Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register.

Journal: Rheumatology (Oxford, England)

Published: March 19, 2018

Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Journal: Annals of the rheumatic diseases

Published: March 08, 2018

Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register.

Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register.

Journal: RMD open

Published: October 08, 2017

Showing 1-12 of 40

Last Updated: 09/26/2026